Nolleca Forbes-Thomas
Neonatal, Critical Care · Newark, NJNPI 1962828152
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Edwards Lifesciences at 30.7% of the total. 2025 is the largest year on record at $736, more than ten times the $61 reported in 2022.
Across 46 payments — averaging $33.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$475
- AbbVie$333
- Cardiva Medical, Inc.$172
- Teva Pharmaceuticals USA, Inc.$144
- E.r. Squibb & Sons, L.L.C.$135
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$70
- plus $221 from 7 others
What the payments were for
- Food & beverage$1,550100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 5 | $475 |
| AbbVie | 20 | $333 |
| Cardiva Medical, Inc. | 2 | $172 |
| Teva Pharmaceuticals USA, Inc. | 4 | $144 |
| E.r. Squibb & Sons, L.L.C. | 1 | $135 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $70 |
| Otsuka America Pharmaceutical, Inc. | 4 | $65 |
| Atricure, Inc. | 1 | $45 |
| Medtronic | 2 | $30 |
| Abiomed | 1 | $29 |
| Alkermes, Inc. | 1 | $19 |
| Angiodynamics, Inc. | 1 | $17 |
| Indivior Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SAPIEN 3 Ultra RESILIA$335
- ELIQUIS$135
- UZEDY$109
How this compares
Too few neonatal, critical care providers in New Jerseyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 19 | $4,066 |
| Quetiapine Fumarate | 16 | $111 |
| Trazodone Hcl | 13 | $34 |
Paid to pharmacies, not to this prescriber.
Other neonatal, critical care in Newark
- Diane McClurePaterson$555
- Barbara WiederCedar Knolls$239
- Ruth SnyderMorristown$200
- Christine WhelanLong Branch$169
- Mini ChackoLivingston$153
- Michele AmbrosinoGreenwich$118
- Linda TurnerVoorhees$116
- Anna HallCedar Knolls$31
- Luann CampagnolaHackensack$13
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.